Article information
El Comité Asesor de Vacunas (CAV) de la Asociación Es-pañola de Pediatría (AEP) comunica en este documento las recomendaciones acerca del calendario vacunal para 2003. De nuevo se insiste en la utilización de vacunas de polio inactivadas, en cualquier edad. Además, se recomienda encarecidamente la introducción de la vacuna de varicela y la vacuna conjugada de neumococo, así como la opción tétanos, difteria tipo adulto ypertussisacelular (dTpa) en adolescentes, por disponerse de productos seguros y eficaces. El creciente número de nuevas vacunas en el calendario vacunal hace necesario emplear estrategias con vacunas combinadas.
Palabras clave:
Enfermedades inmunoprevenibles
Calendario vacunal
Estrategias vacunales
Inmunizaciones
Vacunas
Vacunas combinadas
In this document the Advisory Committee on Vaccines of the Spanish Association of Pediatrics provides recommendations for the immunization schedule for the 2003 season. The use of inactivated poliovirus vaccine is again stressed for children of any age. Moreover, the introduction of the varicella vaccine and the pneumo-coccal conjugated vaccine, as well as the option of dTpa in adolescents, is highly recommended due to the availability of safe and effective products. Because of the increasing number of new vaccines in the immunization schedule, strategies with combined vaccines must be used.
Key words:
Vaccine preventable diseases
Immunization schedule
Vaccination strategies
Immunizations
Vaccines
Combined vaccines
Full text is only aviable in PDF
Bibliografía
[1.]
Comité Asesor de Vacunas de la AEP. Calendario vacunal de la AEP 1999.
An Esp Pediatr, 51 (1999), pp. 120-126
[2.]
Comité Asesor de Vacunas de la AEP. Calendario vacunal de la Asociación Española de Pediatría 2001-2002.
An Esp Pediatr, 55 (2001), pp. 30-38
[3.]
H. Helwig, J. Mertsola, D. Harvey, D. Nicolopoulos, J.C. Schaack, W. Sedlak.
on behalf of the Confederation of European Specialists in Pediatrics (CESP).
J Pediatr, 157 (1998), pp. 676-680
[4.]
R. Dal-Ré, J. Arístegui, A. González.
Inmunidad frente a la difteria en adultos jóvenes en España.
Med Clin (Barc), 17 (1995), pp. 676
[5.]
P. Garcia-Corbeira, R. Dal-Ré, J. García de Lomas, L. Aguilar.
Low prevalence of diphtheria immunity in the Spanish population: results of a cross-sectional study.
Vaccine, 17 (1999), pp. 1978-1982
[6.]
M. Español, C. Muñoz, G. Prats.
Inmunidad frente a la difteria de una muestra representativa de la población de Barcelona determinada mediante una técnica inmunoenzimática.
Vacunas Investigación y Práctica, 1 (2000), pp. 59-64
[7.]
R.L. Jacobs, R.S. Lowe, B.Q. Lanier.
Adverse reactions to tetanus toxoid.
Jama, 247 (1982), pp. 40
[8.]
L.J. Baraff, C.L. Cody, J.D. Cherry.
DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose.
Pediatrics, 73 (1984), pp. 31-36
[9.]
A.E. Jones, M. Melville-Smith, J. Watkins, V. Seagroatt, L. Rice, F. Sheffield.
Adverse reactions in adolescents to reinforcing doses of plain and adsorbed tetanus vaccines.
Community Med, 7 (1985), pp. 99-106
[10.]
CDC. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory Committee (ACIP).
Mmwr, 40 (1991), pp. 1-28
[11.]
Servicio de vigilancia epidemiológica. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo. Comentario epidemiológico de las Enfermedades de Declaración Obligatoria y Sistema de Información Microbiológica. España Año 2000.
Bol Epidemiol Semanal, 9 (2001), pp. 101-112
[12.]
Servicio de vigilancia epidemiológica. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo. Comentario epidemiológico de las Enfermedades de Declaración Obligatoria y Sistema de Información Microbiológica. España. Año 2001.
Bol Epidemiol Semanal, 10 (2002), pp. 49-60
[13.]
A. Gil, I. Oyagüez, P. Carrasco, A. Gonzalez.
Hospital admissions for pertussis in Spain, 1995-1998.
Vaccine, 19 (2001), pp. 4791-4799
[14.]
J.M. Eiros Bouza, R. Ortiz de Lejarazu, A. Orduña Domingo, M.R. Bachiller Luque.
Estudio seroepidemiológico en niños vacunados frente a tos ferina.
An Esp Pediatr, 41 (1994), pp. 285-286
[15.]
P. García Corbeira, R. Dal-Ré, L. Aguilar, J. García de Lomas.
Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross-sectional study.
Vaccine, 18 (2000), pp. 2173-2176
[16.]
M.E. Nennig, H.R. Shinefield, K.M. Edwards, S.B. Black, B.H. Fireman.
Prevalence and incidence of adult pertussis in an urban population.
Jama, 275 (1996), pp. 1672-1674
[19.]
M. Campins-Martí, H.K. Cheng, K. Forsyth, N. Guiso, S. Halperin, L.M Huang.
Recommendations are needed for adolescents and adult pertussis immunisation: rationale ans strategies for consideration.
Vaccine, 20 (2002), pp. 641-646
[20.]
E. Giemprel, S. Baron, D. Lévy-Bruhl, J.M. Garmier, E. N'jamkepo, N. Guiso.
Influence of vaccination coverage on pertussis transmission in France.
Lancet, 354 (1999), pp. 1699-1700
[21.]
F.A. Moraga, M. Campins Martí.
La tos ferina en el lactante y el adolescente.
An Esp Pediatr, 56 (2002), pp. 417-421
[22.]
World Health Organization. Certification of poliomyelitis eradicaction. European Region, June 2001.
Weekly Epidemiological Record, 27 (2002), pp. 221-223
[23.]
American Academy of Pediatrics. Committee of Infectious Diseases: Prevention of poliomyelitis: recommendations for the use of only inactivated poliovirus vaccine for routine immunization.
Pediatrics, 104 (1999), pp. 1404-1406
[24.]
L. Salleras, A. Domínguez.
Prospects for global poliomyelitis eradication.
Vacunas, Investigación y Práctica, 1 (2000), pp. 178-187
[25.]
P. Beutels, W.J. Edmunds, F. Antoñanzas, G.A. De Wit, D. Evans, R. Feilden.
Economic Evaluation of vaccination programmes. A consensus statement focusing on viral hepatitis.
Pharmacoeconomics, 20 (2002), pp. 1-7
[26.]
P. Beutels.
Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).
Health Econ, 10 (2001), pp. 751-774
[27.]
M. Kane, J. Banatvala, G. Da Villa.
Are booster immunizations hended for lifelong hepatitis B immunityα Consensus statement.
Lancet, 355 (2000), pp. 561-565
[28.]
P.L. Lopalco, L. Salleras, S. Barbuti, C. Germinario, M. Bruguera, M. Buti.
Hepatitis A and B in children and adolescentswhat can we learn from Puglia (Italy) and Catalonia (Spain)α.
Vaccine, 19 (2000), pp. 470-474
[29.]
Dirección General de Salud Pública. Ministerio de Sanidad y Consumo.Programas de vacunación frente a la hepatitis B en adolescentes. Periodo 1996-1997.
Bol Epidemiol Semanal, 6 (1998), pp. 209-210
[30.]
J.H. Kao, D.S. Chen.
Global control of hepatitis B virus infection.
Lancet Infect Dis, 2 (2002), pp. 395-403
[31.]
P. Van Damme, A. Vorsters.
Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001.
J Med Virol, 67 (2002), pp. 433-439
[32.]
J. Eskola, J. Ward, R. Dagan, D. Goldblatt, F. Zepp, C.A. Siegrist.
Haemophilus influenzae tipo b (Hib) conjugate vaccines administered in combination with DTP containing acellular pertussis and protection against invasive Hib disease.
Lancet, 354 (1999), pp. 2036-2038
[33.]
H.J. Schmitt, F. Zepp, S. Muschenbord, G. Sumenicht, A. Schuind, K. Beutel.
Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphteriatetanus- toxoid and acellular pertussis vaccine for primary and for booster immunizations.
Eur J Pediatr, 157 (1998), pp. 208-214
[34.]
F. Zepp, A. Schuind, C. Meyer, R. Sanger, A. Kaufhold, P. Willems.
Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants.
Pediatrics, 109 (2002), pp. 58
[35.]
H. Cody Meissner, L.K. Pickering.
Control of disease attributable to Haemophilus influenzae type b and the national immunization program.
Pediatrics, 110 (2002), pp. 820-822
[36.]
F. Zhou, K.M. Bisgard, H.R. Yusuf, R.R. Deuson, S.K. Bath, T.V. Murphy.
Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis.
Pediatrics, 110 (2002), pp. 653-661
[37.]
American Academy of Pediatrics. Committee on Infectious Diseases. Age for Routine Administration of the second dose of measles-mumps-rubella vaccine.
Pediatrics, 101 (1998), pp. 129-133
[38.]
W.A. Orenstein, P.M. Strebel, M. Papania, R.W. Sutter, W.J. Bellini, S.L. Cochi.
Measles erradication: Is it in out futureα.
Am J Public Health, 90 (2000), pp. 1521-1525
[39.]
S. Mateo, R. Cano, C. García.
Changing epidemiology of meningococcal disease in Spain, 1989-1997.
Eurosurveillance, 2 (1997), pp. 71-74
[40.]
J.M. MacLennan, F. Shackley, P.T. Health, J.J. Deeks, C. Flamank, M. Herbert.
Safety, immunogenicity and induction of immunologic memory by a serogroup C conjugate vaccine in infants.
Jama, 283 (2000), pp. 2795-2801
[41.]
M.B. Rennels, K.M. Edwards, H.L. Keyserling, K.S. Reisinger, M.M. Blatter, A. Sally.
Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.
Pediatr Infect Dis J, 20 (2001), pp. 153-159
[42.]
P. Richmond, R. Borrow, E. Miller, S. Clark, F. Sadler, A. Fox.
Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.
J Infect Dis, 179 (1999), pp. 1569-1572
[43.]
A.M. Arberter.
Clinical trials of varicella vaccine in healthy adolescents and adults.
Infect Dis Clin North Am, 10 (1996), pp. 609-615
[44.]
J.A. Gómez Campderá.
Vacuna antivaricela.
Acta Pediatr Esp, 59 (2001), pp. 345-355
[45.]
J.C. Srabstein, N. Morris, B. Larke, D. deSa, D.P. Oxon, B.B. Castelino.
Is there a congenital varicella syndromeα.
J Pediatr, 84 (1974), pp. 239-243
[46.]
A.A. Gershon, P. LaRusa, S. Steinberg.
Clinical trials in immunocompromised individuals.
Infect Dis Clib North Am, 10 (1996), pp. 583-594
[47.]
R.P. Wise, M.E. Salive, M.M. Braun, G.T. Mootrey, J.F. Seward, L.G. Rider.
Postlicensure safety surveillance for varicella vaccina.
Jama, 284 (2000), pp. 1271-1279
[48.]
F. Moraga LLop, M.J. García de Miguel, E. Giangaspro, J. Roca, F. Baquero, J.A. Gómez Campderá.
Coste de la hospitalización por varicela en niños inmunocompetentes.
Vacunas, 2 (2001), pp. 20-24
[49.]
J. Diez Domingo, M. Ridao, J. Latour, A. Ballester, A. Morant.
A cost benefit analysis of routine varicella vaccination in Spain.
Vaccine, 17 (1999), pp. 1306-1311
[50.]
C. De Lucas, J.A. Gómez Campderá, M.L. Navarro Gómez, R. Rodríguez Fernández.
Complicaciones de la varicela en niños previamente sanos.
Rev Esp Pediatr, 53 (1997), pp. 320-324
[51.]
G. Angeles Fernández, J. Villanueva Lamas, F.J. Cambra, M.a T Toll, A. Palomeque Ricao.
Purpura fulminans posvaricela con déficit transitorio de proteína C y proteína S.
An Esp Pediatr, 49 (1998), pp. 412-414
[52.]
M. Riaza Gómez, M. De la Torre Espi, S. Mencia Bartolomé, J.C. Molina Cabalero, A. Tamariz-Martel Moreno.
Complicaciones de la varicela en niños.
An Esp Pediatr, 50 (1999), pp. 259-262
[53.]
A. Casado, M. García Calvo, A. Pérez, M. Rodríguez Créixems.
Incidencia de las infecciones neumocócicas pediátricas en España. Revisión bibliográfica.
An Esp Pediatr, 57 (2002), pp. 7-13
[54.]
E. Bernaola, J. de Aristegui, M. Herranz, C. García-Calvo, C. Fernández.
Estudio de la incidencia de enfermedad neumocócica invasora entre 0-5 años en el País-Vasco y Navarra.
An Esp Pediatr, 57 (2002), pp. 301-309
[55.]
C. Pérez, G. Solis, D. Miguel, P. De la Iglesia, G. Viejo, M. Martín.
Factores predictivos de enfermedad neumocócica invasora: estudio de casos controles.
An Esp Pediatr, 57 (2002), pp. 310-316
[56.]
V. Pineda Solas, A. Pérez Benito, M. Domingo Puiggros, H. Larramona Carrera, F. Segura Prota, D. Fontanals Aymerich.
Neumonía neumocócica bacteriémica.
An Esp Pediatr, 57 (2002), pp. 408-413
[57.]
J. Casado Flores, A. Fenol, J. Aristegui, C. Rodrigo de Liria, J.M. Martinón, C. Fernández.
y Grupo para el Estudio de la Meningitis Neumocócica. Meningitis neumocócica en niños españoles: incidencia, serotipos y resistencia antibiótica. Estudio prospective multicéntrico.
An Esp Pediatr, 57 (2002), pp. 287-289
[58.]
J.J. Picazo, C. Betriu, I. Rodríguez-Aviar, E. Azahares.
Alí Sánchez B y Grupo VIRA. Vigilancia de resistencias a los antimicrobianos: estudio VIRA.
Enferm Infecc Microbiol Clin, 20 (2002), pp. 503-510
[59.]
S. Black, H. Shinefield, B. Fireman, E. Lewis, P. Ray, J.R. Hansen.
The Northern California Kaiser Permanent Vaccine Study Center Group. Efficacy, safety and inmunogenicity of a heptavalent pneumococcal conjugate vaccine in children.
Pediatr Infect Dis J, 19 (2000), pp. 187-195
[60.]
S. Black, H. Shinefield, S. Ling, J. Hansen, B. Fireman, D. Spring.
The Northern California Kaiser Permanent Vaccine Study Center Group. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.
Pediatr Infect Dis J, 21 (2002), pp. 810-815
[61.]
A. Fenoll, Y. Jado, D. Vicioso, S. Berron, J.E. Yuste, J. Casal.
Streptococcus pneumoniae in children in Spain: 1990-1999.
Acta Pediatr, 135 (2000), pp. 44-50
[62.]
V. Pineda, D. Fontanals, H. Larramona, M. Domingo, J. Anton, F. Segura.
Epidemiology of invasive Streptococcus pneumonia infections in children in an area of Barcelona, Spain.
Acta Paediatr, 91 (2002), pp. 1251-1256
[63.]
Comité Asesor de Vacunas de la Asociación Española de Pediatría. Incidencia de la infección neumocócica invasora en niños menores de dos años. Vacuna neumocócica conjugada heptavalente. Situación en España.
An Esp Pediatr, 57 (2002), pp. 287-289
[64.]
Comité Asesor de Vacunas de la Asociación Española de Pediatría. La enfermedad neumocócica y su prevención. Vacuna neumocócica conjugada heptavalente.
An Esp Pediatr, 56 (2002), pp. 79-90
[65.]
J.G. Liese, S. Stojanov, F. Berut, P. Minini, E. Harzer, S. Jow.
and Munich Vaccine Study Group. Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP-T-HBs) administered at 2, 4, 6 and 12-14 months of age.
Vaccine, 20 (2001), pp. 448-454
[66.]
E. Mallet, P. Fabre, E. Pines, H. Salomon, T. Staub, F. Schodel.
and Hexavalent Vaccine Trial Study Group. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccine in infants.
Pediatr Infect Dis J, 19 (2000), pp. 1119-1127
[67.]
H.J. Schmitt, R. von Kries, B. Hassenpflug, M. Hermann, A. Siedler, W. Niessing.
Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus)/H. influenzae type b combination vaccines.
Pediatr Infect Dis J, 20 (2001), pp. 767-774
Copyright © 2003. Asociación Española de Pediatría
